Search Results for "Cancer Diagnostics"

19:24 EDT 24th May 2015 | BioPortfolio

Matching Channels

Roche

Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

Nasopharyngeal Cancer

Rectal cancer

Vulvar Cancer

Vaginal Cancer

Matching News

Global Cancer Diagnostics grants first international license for The Lung Cancer Test to Bertech

Global Cancer Diagnostics announced the signing of a license agreement with Bertech Diagnostics of Edmonton, Alberta.

2014-2018 US Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

"2014 Opportunities in the US Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The...

2014-2018 UK Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

"2014 Opportunities in the UK Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.  The...

Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation

The lack of accurate tools for diagnosing the severity of prostate cancer creates opportunities for start-ups with novel approaches. Profiles of 3D Biopsy, Blue Earth Diagnostics, UroSens, and Prostat...

Laying the Foundation for Next-Gen Cancer Diagnostics

Bio-IT World | This summer, Foundation Medicine will launch what could be described as the next generation of cancer diagnostics. The Cambridge, Mass.-based company, founded by a premier group of can...

Miroculus raises $2.3M for low-cost blood test that detects multiple types of cancer

  Diagnostics startup Miroculus became a bit of a media darling last fall, in part from its TED Talk on bringing inexpensive, rapid-fire cancer diagnostics to the developing world. The Bay...

Agendia – decoding cancer

Agendia is a leading molecular diagnostics company developing FFPE-based genomic diagnostic products, allowing clinically relevant gene expression profiling for cancer patients. Agendia – decod...

Start-Up Previews, April 2015

This Month's Profile Group, Prostate Cancer Diagnostics, features profiles of 3DBiopsy, Blue Earth Diagnostics, Prostate Management Diagnostics, and UroSens. Plus these Start-Ups Across Health Care: G...

Matching PubMed Articles

Current situation and challenges in companion diagnostics development.

The personalized health care, it is defined as a medical care which provide the optimal therapy for each individual in consideration of a patient's individual difference, such as a genetic background ...

Criteria of the molecular pathology testing of lung cancer.

From the aspect of the contemporary pathologic diagnostics of lung cancer the tissue obtained is a key issue since small biopsies and cytology still play a major role. In the non-small cell lung cance...

Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.

To apply an individualized oncological approach to gastric cancer patients, the accurate diagnosis of disease entities is required. Peritoneal metastasis is the most frequent mode of metastasis in gas...

Gender Differences in Lung Cancer.

More and more women suffer from lung cancer. In comparison to the male patients they are younger and more likely never-smokers. Adenocarcinomas are more frequently in women than in men. Their long-tim...

Reproducible and Reliable Real-time PCR Assay to Measure Mature Form of miR-141.

miR-141 is one of the miRNAs that has significant expression variations in different human malignancies including prostate cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ga...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement